Beneficial Ownership Report · SCHEDULE 13G/A
Bicara Therapeutics Inc.
BCAXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- BICARA THERAPEUTICS INC
- Company CIK
- 0002023658
- Street
- 245 MAIN STREET
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 2142
Statement details
- Amendment number
- 2
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- T. Rowe Price Investment Management, Inc.
- Citizenship / organization
- MD
- Reporting person type
- IA
- Aggregate amount owned
- 2,804,772
- Percent of class
- 4.2
- Sole voting power
- 2,798,430
- Shared voting power
- 0
- Sole dispositive power
- 2,804,772
- Shared dispositive power
- 0
- Aggregate excludes certain shares
- N
Item 1
Issuer
BICARA THERAPEUTICS INC
Principal executive office address
245 MAIN STREET, CAMBRIDGE, MA, 2142
Item 2
Citizenship
Maryland
Filing person
T. Rowe Price Investment Management, Inc.
Principal business or residence address
1307 Point Street, Baltimore, MD 21231
Item 3
Not applicable indication
N
Type of filing person
IA
Item 4
Percent of class
4.2
Amount beneficially owned
2804772
Sole voting power
2798430
Shared voting power
0
Sole dispositive power
2804772
Shared dispositive power
0
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
Signature 1
- Reporting person
- T. Rowe Price Investment Management, Inc.
- Signed
- Ellen York
- Title
- Vice President
- Date
- 10/07/2026